Renaissance Capital logo

BLCM News

US IPO Weekly Recap: Record 2014 IPO market finishes with a $2 billion cancer biotech

Four companies went public in the past week and brought the final IPO count of 2014 up to 275 deals that raised $85 billion, making it the most active year for the IPO market since 2000. The year's record biotech boom was capped by Juno Therapeutics (+46%), the largest biotech IPO in at least 15 years. Online lender On Deck Capital (+21%) also raised investor interest in a week that...read more

Bellicum Pharmaceuticals prices upsized IPO at $19, above the range

Bellicum Pharmaceuticals, an early-stage biotech developing controllable cancer immunotherapies, raised $140 million by offering 7.35 million shares (vs. 6.25 originally planned) at $19, above its $15 to $17 range. Bellicum will list on the NASDAQ under the symbol BLCM. Jefferies, Citi and Piper Jaffray acted as joint bookrunners on the deal....read more

Week ahead: The 2014 IPO market's final round with 6 IPOs planned for the week of Dec 15

Six deals are on the IPO calendar looking to raise a combined $1.0 billion during the week of December 15, 2014. Half of the deals are biotech IPOs, including the largest of the year by market cap (Juno Therapeutics; $1.5 billion). Following last week’s surge of six technology IPOs, none are on the...read more

Double dose of immunotherapy: Bellicum Pharmaceuticals sets terms for $100 million IPO

Bellicum Pharmaceuticals, which is developing adjunct cancer immunotherapies based on a conditionally responsive platform, announced terms for its IPO on Tuesday. The Houston, TX-based company plans to raise $100 million by offering 6.3 million shares at a price range of $15 to $17. At the midpoint of the proposed range, Bellicum Pharmaceuticals would command a fully diluted market...read more